Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gisselbrecht

Showing results (181-190 of 215) with videos related to

Pageof 22
Sort By:
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphomaA Bosly, E Lepage, B Coiffier, et al.
Bone Marrow Transplantation|October 9, 2007
Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphomaC Gisselbrecht, W Bethge, R F Duarte, et al.
Bone Marrow Transplantation|November 1, 1996
Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancerC Gisselbrecht, J M Extra, J P Lotz, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|June 26, 2001
Factors affecting hematopoietic recovery after autologous peripheral blood progenitor-cell transplantation in aggressive non-Hodgkin's lymphoma: a prospective study of 123 patientsA M Langouët, P Brice, D Simon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2007
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2P Morel, P Gaulard, C Gisselbrecht, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomasK Leroy, C Haioun, E Lepage, et al.
Blood|June 25, 1998
Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)C Gisselbrecht, P Gaulard, E Lepage, et al.
Blood|August 29, 2000
Prognostic significance of survivin expression in diffuse large B-cell lymphomasC Adida, C Haioun, P Gaulard, et al.
Haematologica|May 9, 2000
Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'AdulteR O Casasnovas, C Haioun, C Dumontet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2008
Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop CriteriaJ Dupuis, E Itti, A Rahmouni, et al.
Pageof 22

Showing results (181-190 of 215) with videos related to

Sort By:
Pageof 22
The Hematology Journal : the Official Journal of the European Haematology Association|March 29, 2002
Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphomaA Bosly, E Lepage, B Coiffier, et al.
Bone Marrow Transplantation|October 9, 2007
Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphomaC Gisselbrecht, W Bethge, R F Duarte, et al.
Bone Marrow Transplantation|November 1, 1996
Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancerC Gisselbrecht, J M Extra, J P Lotz, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|June 26, 2001
Factors affecting hematopoietic recovery after autologous peripheral blood progenitor-cell transplantation in aggressive non-Hodgkin's lymphoma: a prospective study of 123 patientsA M Langouët, P Brice, D Simon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2007
Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2P Morel, P Gaulard, C Gisselbrecht, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomasK Leroy, C Haioun, E Lepage, et al.
Blood|June 25, 1998
Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)C Gisselbrecht, P Gaulard, E Lepage, et al.
Blood|August 29, 2000
Prognostic significance of survivin expression in diffuse large B-cell lymphomasC Adida, C Haioun, P Gaulard, et al.
Haematologica|May 9, 2000
Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'AdulteR O Casasnovas, C Haioun, C Dumontet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2008
Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop CriteriaJ Dupuis, E Itti, A Rahmouni, et al.
Pageof 22